James Sillibourne (below) is Director of Synthetic Genomics at Autolus Therapeutics (London, UK), a biotech company focussing on developing chimeric antigen-receptor T-cell (CAR-T) therapies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results